Literature DB >> 10360646

Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.

B Cenni1, H K Kim, G J Bubley, S Aebi, D Fink, B A Teicher, S B Howell, R D Christen.   

Abstract

In addition to recognizing and repairing mismatched bases in DNA, the mismatch repair (MMR) system also detects cisplatin DNA adducts and loss of MMR results in resistance to cisplatin. A comparison was made of the ability of MMR-proficient and -deficient cells to remove cisplatin adducts from their genome and to reactivate a transiently transfected plasmid that had previously been inactivated by cisplatin to express the firefly luciferase enzyme. MMR deficiency due to loss of hMLH1 function did not change the extent of platinum (Pt) accumulation or kinetics of removal from total cellular DNA. However, MMR-deficient cells, lacking either hMLH1 or hMSH2, generated twofold more luciferase activity from a cisplatin-damaged reporter plasmid than their MMR-proficient counterparts. Thus, detection of the cisplatin adducts by the MMR system reduced the efficiency of reactivation of the damaged luciferase gene compared to cells lacking this detector. The twofold reduction in reactivation efficiency was of the same order of magnitude as the difference in cisplatin sensitivity between the MMR-proficient and -deficient cells. We conclude that although MMR-proficient and -deficient cells remove Pt from their genome at equal rates, the loss of a functional MMR system facilitates the reactivation of a cisplatin-damaged reporter gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360646      PMCID: PMC2362265          DOI: 10.1038/sj.bjc.6690412

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Loss of DNA mismatch repair in acquired resistance to cisplatin.

Authors:  S Aebi; B Kurdi-Haidar; R Gordon; B Cenni; H Zheng; D Fink; R D Christen; C R Boland; M Koi; R Fishel; S B Howell
Journal:  Cancer Res       Date:  1996-07-01       Impact factor: 12.701

2.  Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  J M Carethers; M T Hawn; D P Chauhan; M C Luce; G Marra; M Koi; C R Boland
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  The role of DNA mismatch repair in platinum drug resistance.

Authors:  D Fink; S Nebel; S Aebi; H Zheng; B Cenni; A Nehmé; R D Christen; S B Howell
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

4.  Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems.

Authors:  D Mu; M Tursun; D R Duckett; J T Drummond; P Modrich; A Sancar
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

5.  Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6.

Authors:  A Umar; M Koi; J I Risinger; W E Glaab; K R Tindall; R D Kolodner; C R Boland; J C Barrett; T A Kunkel
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

6.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

Authors:  D Fink; H Zheng; S Nebel; P S Norris; S Aebi; T P Lin; A Nehmé; R D Christen; M Haas; C L MacLeod; S B Howell
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

7.  Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line.

Authors:  J T Drummond; A Anthoney; R Brown; P Modrich
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

8.  The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.

Authors:  J A Mello; S Acharya; R Fishel; J M Essigmann
Journal:  Chem Biol       Date:  1996-07

9.  Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.

Authors:  S Aebi; D Fink; R Gordon; H K Kim; H Zheng; J L Fink; S B Howell
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

10.  Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines.

Authors:  J C Boyer; A Umar; J I Risinger; J R Lipford; M Kane; S Yin; J C Barrett; R D Kolodner; T A Kunkel
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

View more
  4 in total

1.  Protective role of Puralpha to cisplatin.

Authors:  Rafal Kaminski; Armine Darbinyan; Nana Merabova; Satish L Deshmane; Martyn K White; Kamel Khalili
Journal:  Cancer Biol Ther       Date:  2008-12-08       Impact factor: 4.742

2.  A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies.

Authors:  Yongliang Zhang; Jennifer T Fox; Young-Un Park; Gene Elliott; Ganesha Rai; Mengli Cai; Srilatha Sakamuru; Ruili Huang; Menghang Xia; Kyeryoung Lee; Min Ho Jeon; Bijoy P Mathew; Hee Dong Park; Winfried Edelmann; Chan Young Park; Sung You Hong; David Maloney; Kyungjae Myung
Journal:  Cancer Res       Date:  2016-06-04       Impact factor: 12.701

3.  Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells.

Authors:  Chung-Chun Wu; Ming-Tsan Liu; Yu-Ting Chang; Chih-Yeu Fang; Sheng-Ping Chou; Hsin-Wei Liao; Kuan-Lin Kuo; Shih-Lung Hsu; Yi-Ren Chen; Pei-Wen Wang; Yu-Lian Chen; Hsin-Ying Chuang; Chia-Huei Lee; Ming Chen; Wun-Shaing Wayne Chang; Jen-Yang Chen
Journal:  Nucleic Acids Res       Date:  2009-12-23       Impact factor: 16.971

4.  Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Akshada Sawant; Venkata Srinivas Mohan Nimai Dangeti; Robert W Sobol; Steve M Patrick
Journal:  Nucleic Acids Res       Date:  2013-06-12       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.